GlassScriptPhysician profile
Jessica Lyn Brown
NPI 1821171760
$4,646.56
in general payments reported to CMS, 2019-2025
31 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Pediatric Pulmonology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $658 · 2021: $808 · 2022: $681 · 2023: $794 · 2024: $521 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,559 · Education: $61.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,559.35 |
| Education | $61.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $526.06 | 2019-2025 | Nucala |
| Jazz Pharmaceuticals INC. | $503.02 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $460.17 | 2020-2025 | Airsupra, Fasenra, Tezspire |
| Baxter Healthcare | $373.66 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| Csl Behring | $327.71 | 2020-2024 | Hizentra, Haegarda |
| Harmony Biosciences LLC | $320.01 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $264.18 | 2019-2021 | |
| Advanced Respiratory, INC | $256.84 | 2019-2021 | |
| Eisai INC. | $239.76 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $204.06 | 2020-2023 | |
| Horizon Therapeutics Plc | $172.17 | 2020-2023 | Ravicti |
| Biogen, INC. | $148.56 | 2021-2024 | Leqembi |
| Alk-Abello, INC | $121.36 | 2020-2022 | |
| Acadia Pharmaceuticals INC | $67.85 | 2023-2025 | Daybue |
| Almatica Pharma LLC | $67.79 | 2022-2024 | Loreev Xr |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $66.67 | 2021-2022 | |
| Grifols USA, LLC | $66.06 | 2020-2023 | Xembify |
| Adma Biomanufacturing LLC | $58.85 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.16 | 2020-2021 | |
| Amgen INC. | $48.00 | 2022-2023 | Tezspire |
| Optinose US, INC. | $42.59 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $41.03 | 2021-2022 | |
| Pharming Healthcare, INC. | $40.69 | 2021-2022 | |
| Kaleo, INC. | $35.00 | 2021 | |
| Sobi, INC | $31.79 | 2019-2022 | |
| Abbvie INC. | $25.72 | 2025 | |
| Axsome Therapeutics, INC. | $21.33 | 2025 | Sunosi |
| Cumberland Pharmaceuticals, INC. | $19.12 | 2019 | |
| Biocryst US Sales Co., LLC | $15.86 | 2023 | Orladeyo |
| Biocryst Pharmaceuticals, INC. | $15.06 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.